cells within liver tumour mass comprise a unique set of proteins / tumour antigens when compared to the normal liver tissues epithelial cells juxtaposed to the tumour . the presence of tumour antigens couples the production of auto - antibodies against these tumour antigens . the present invention relates to the identification and elucidation of a protein set that can act as a novel marker set for liver cancer diagnosis and prognosis . specifically , it relates to a kit that enables diagnostic and prognostic measurement of auto - antibodies in serum of liver cancer patients . the present invention provides a non - invasive , specific , sensitive , and cost effective detection and quantification method by evaluating a set of validated liver cancer proteins / tumour antigens , which includes bmi - 1 , vcc1 , sumo - 4 , rhoa , txn , et - 1 , ube2c , hdgf2 , fgf21 , lect2 , sod1 , stmn4 , midkine , il - 17a or il26 , to complement the conventional diagnostic methods .